Maintained improvement with minocycline of a patient with advanced Huntington's disease

Journal of Psychopharmacology

Volumn 16, Issue 4, 2002, Pages 393-394

  Denovan Wright, E M ^a   Devarajan, S ^a   Dursun, S M ^a   Robertson, H A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antiapoptotic agent; Antibiotic; Basal ganglia; Neurodegeneration; Tetracycline

Indexed keywords

CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; LOXAPINE; MINOCYCLINE; NEUROLEPTIC AGENT; OLANZAPINE; TETRABENAZINE; VALPROIC ACID;

ADULT; ARTICLE; BASAL GANGLION; CASE REPORT; CHOREA; DEGENERATIVE DISEASE; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; LEUKOPENIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0242432635     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110201600417     Document Type: Article

References (3)

1. Chen M, Ona VO, Li M, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med 6: 797-801
2. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983
3. Mangiarini L, Sathasivam K, Seller M, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506